

Bharat Biotech International (BBIL) on Friday signed an agreement with Gavi, the Vaccine Alliance, and UNICEF to cut the price of the world’s first malaria vaccine, RTS,S/AS01, by 40% to 5.50 euros per dose.
The new price is expected to take effect in early 2027.
The price reduction is expected to help protect an additional one million children with the full four-dose course and save $50 mn for child immunisation programmes between 2027 and 2029, according to the company.
Developed by GSK, PATH and partners, RTS,S/AS01 was the first malaria vaccine recommended by the World Health Organization (WHO) in 2021. Bharat Biotech now manufactures the vaccine under the brand name Mosqivac.
BBIL chairman Krishna Ella said the agreement would expand access to malaria vaccination. “We have invested significantly to expand supply, strengthen manufacturing and support sustainable, affordable access to malaria vaccines,” he said.
The price cut is expected to support the alliance’s goal of vaccinating 50 million more children against malaria by 2030.
GSK chief global health officer Harmony P Garges said the agreement followed substantial investments by GSK and BBIL to secure long-term equitable access to the vaccine. He added that partnerships were increasingly important as global health resources came under pressure.
Since the rollout began in 2024, demand for malaria vaccines has exceeded initial forecasts, with UNICEF procuring and delivering 74 million doses. The Gavi-funded programme has been integrated into routine immunisation in 25 African countries that account for more than 70% of the global malaria burden.
The price cut is expected to support the alliance’s goal of vaccinating 50 million more children against malaria by 2030.
In 2024, there were an estimated 282 million malaria cases and 6,10,000 deaths globally – with up to 95% of cases and around 74% of deaths occurring in Africa.